Pharmacology Quiz: Biologics And Immunosuppressants

20 questions · exam conditions

0:00

Biologics And ImmunosuppressantsQuestion 1 of 20

A patient with rheumatoid arthritis is prescribed etanercept. How does the fundamental structure of this biologic agent differ from that of a monoclonal antibody like adalimumab, even though both are effective TNF-alpha inhibitors?

Etanercept is a humanized monoclonal antibody, whereas adalimumab is a fully human one.

Etanercept is a fusion protein composed of two p75 TNF receptors linked to the Fc portion of human IgG1.

Etanercept is a chemically synthesized peptide that mimics the binding site of the TNF-alpha receptor.

Etanercept is an antibody-drug conjugate that delivers a cytotoxic payload to TNF-expressing cells.

← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Biologics And Immunosuppressants

Practice Biologics And Immunosuppressants in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Biologics And Immunosuppressants, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Etanercept is a humanized monoclonal antibody, whereas adalimumab is a fully human one.
Etanercept is a fusion protein composed of two p75 TNF receptors linked to the Fc portion of human IgG1. (correct answer)
Etanercept is a chemically synthesized peptide that mimics the binding site of the TNF-alpha receptor.
Etanercept is an antibody-drug conjugate that delivers a cytotoxic payload to TNF-expressing cells.

Explanation: Etanercept is not a monoclonal antibody; it is a fusion protein. Its structure consists of the extracellular ligand-binding portion of the human tumor necrosis factor receptor (TNFR) p75 fused to the Fc portion of human IgG1. It acts as a soluble 'decoy receptor,' binding to TNF-alpha and preventing it from interacting with cell surface receptors. Monoclonal antibodies like adalimumab are complete antibody structures that bind to TNF-alpha.

Question 2

A 65-year-old patient who has been on various immunosuppressants for psoriasis for over a decade is diagnosed with squamous cell carcinoma of the skin. This common long-term complication of immunosuppressive therapy is primarily attributed to which mechanism?

Direct mutagenic activity of the immunosuppressant drugs on keratinocyte DNA.
A drug-induced increase in skin sensitivity to ultraviolet (UV) radiation.
Impairment of the immune system's ability to recognize and eliminate nascent malignant cells. (correct answer)
Chronic stimulation of keratinocyte proliferation by the biologic agents.

Explanation: The immune system plays a critical role in 'immune surveillance,' which is the process of identifying and destroying cells that have undergone malignant transformation. Long-term immunosuppression, regardless of the specific agent, blunts this surveillance mechanism. This allows potentially cancerous cells, which may arise from various insults like UV radiation, to evade destruction and proliferate, leading to an increased risk of malignancies, particularly skin cancers and lymphomas.

Question 3

A patient with relapsing-remitting multiple sclerosis is being considered for treatment with ocrelizumab. The primary therapeutic mechanism of this biologic agent involves which of the following actions?

Blocking the trafficking of lymphocytes across the blood-brain barrier by targeting α4-integrin.
Depleting CD20-expressing B-lymphocytes from circulation. (correct answer)
Neutralizing the pro-inflammatory cytokine Interleukin-17 (IL-17).
Inhibiting T-cell activation by blocking the CD28 co-stimulatory signal.

Explanation: Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B cells, mature B-cells, and memory B-cells, but not on stem cells or plasma cells. By binding to CD20, it leads to the depletion of these B-cell populations through antibody-dependent cell-mediated cytotoxicity and other mechanisms. This is its primary mechanism of action in multiple sclerosis.

Question 4

Blocking the trafficking of lymphocytes across the blood-brain barrier by targeting α4-integrin.
Depleting CD20-expressing B-lymphocytes from circulation. (correct answer)
Neutralizing the pro-inflammatory cytokine Interleukin-17 (IL-17).
Inhibiting T-cell activation by blocking the CD28 co-stimulatory signal.

Question 5

A new biologic drug named 'zircivizumab' is in late-stage clinical trials. Based on the established international nonproprietary name (INN) conventions for monoclonal antibodies, what is the most likely structure and target of this agent?

A chimeric monoclonal antibody targeting the immune system.
A human monoclonal antibody targeting a tumor antigen.
A humanized monoclonal antibody targeting the cardiovascular system. (correct answer)
A rat-murine hybrid antibody targeting a bacterial infection.

Explanation: The INN nomenclature for monoclonal antibodies can be decoded. The suffix '-mab' indicates it is a monoclonal antibody. The source infix '-zu-' signifies that the antibody is humanized (i.e., murine CDRs grafted onto a human framework). The target infix '-ci-' or '-cir-' refers to the circulatory or cardiovascular system. Therefore, zircivizumab is most likely a humanized monoclonal antibody targeting the cardiovascular system.

Question 6

A patient received a kidney transplant 6 months ago and is maintained on a triple-immunosuppressive regimen of tacrolimus, mycophenolate mofetil, and prednisone. The patient presents with fever, cough, and a new infiltrate on chest x-ray, concerning for an opportunistic infection like Pneumocystis jirovecii pneumonia.

This clinical presentation highlights a major risk resulting from the combined mechanisms of action of the patient's medication regimen, which primarily aims to achieve what overall immunological effect?

Selective depletion of memory B-lymphocytes to prevent antibody-mediated rejection.
Broad and non-specific inhibition of T-lymphocyte activation, proliferation, and effector function. (correct answer)
Targeted neutralization of a single pro-inflammatory cytokine, such as tumor necrosis factor-alpha (TNF-α).
Enhancement of regulatory T-cell (Treg) function to promote long-term allograft tolerance.

Explanation: The combination of a calcineurin inhibitor (tacrolimus), an antimetabolite (mycophenolate), and a corticosteroid (prednisone) provides powerful, broad-spectrum immunosuppression. Their synergistic effect is to block multiple T-cell signaling and proliferation pathways. This profound T-cell inhibition is necessary to prevent transplant rejection but also severely impairs the body's ability to fight off opportunistic pathogens, leading to the clinical scenario described.

Question 7

A chimeric monoclonal antibody targeting the immune system.
A human monoclonal antibody targeting a tumor antigen.
A humanized monoclonal antibody targeting the cardiovascular system. (correct answer)
A rat-murine hybrid antibody targeting a bacterial infection.

Question 8

Etanercept is a humanized monoclonal antibody, whereas adalimumab is a fully human one.
Etanercept is a fusion protein composed of two p75 TNF receptors linked to the Fc portion of human IgG1. (correct answer)
Etanercept is a chemically synthesized peptide that mimics the binding site of the TNF-alpha receptor.
Etanercept is an antibody-drug conjugate that delivers a cytotoxic payload to TNF-expressing cells.

Question 9

A 45-year-old patient with rheumatoid arthritis is receiving their first-ever intravenous infusion of infliximab. Thirty minutes into the infusion, the patient develops chills, rigors, dyspnea, and a significant drop in blood pressure.

This acute adverse event is most likely caused by which pharmacological mechanism?

An IgE-mediated, type I hypersensitivity reaction to murine proteins in the chimeric antibody.
Rapid release of pro-inflammatory cytokines from immune cells activated by the antibody-antigen complex. (correct answer)
Formation and deposition of drug-ADA immune complexes, leading to a type III hypersensitivity reaction.
A delayed type IV hypersensitivity reaction mediated by T-cells sensitized to the biologic agent.

Explanation: This clinical presentation is classic for an infusion reaction, which is often a form of cytokine release syndrome (CRS). It is particularly common with the first infusion of certain biologics. The binding of the antibody (infliximab) to its target (TNF-alpha) and to Fc receptors on immune cells can trigger a massive and rapid release of cytokines (e.g., TNF-alpha, IL-6), leading to systemic inflammatory symptoms. While a type I reaction is possible, CRS is a more common explanation for first-dose reactions of this nature. Type III and IV reactions are delayed and would not occur within minutes of the first infusion.

Question 10

A 58-year-old patient with severe Crohn's disease is a candidate for therapy with a TNF-alpha inhibitor. The patient's medical history is significant for travel to Southeast Asia and a positive tuberculin skin test (TST) 10 years ago, for which they did not receive treatment. A chest X-ray is currently negative for active disease. What is the most critical step to take before initiating the TNF-alpha inhibitor?

Initiate treatment for latent tuberculosis infection (LTBI) and delay the start of the biologic agent. (correct answer)
Proceed with the TNF-alpha inhibitor, as the negative chest X-ray rules out any risk of tuberculosis.
Administer a dose of the BCG vaccine to bolster the patient's immunity against tuberculosis.
Select an alternative biologic from a class that does not carry a risk of TB reactivation, such as an IL-12/23 inhibitor.

Explanation: TNF-alpha is a critical cytokine for containing Mycobacterium tuberculosis within granulomas. Blocking TNF-alpha can lead to the reactivation of latent TB infection (LTBI). Standard guidelines mandate screening for LTBI before starting TNF-alpha inhibitors. In a patient with evidence of LTBI (a positive TST), treatment for LTBI (e.g., with isoniazid) must be initiated before starting the immunosuppressive biologic to prevent life-threatening reactivation. A negative chest X-ray only rules out active pulmonary disease, not latent infection.

Question 11

A research team successfully develops a therapeutic monoclonal antibody in mice. To prepare it for human clinical trials, they undertake a process of "humanization" to reduce its immunogenicity. This process primarily involves which of the following genetic engineering steps?

Replacing the entire murine antibody with a functionally similar antibody isolated from human donors.
Fusing the antigen-binding fragments (Fab) of the murine antibody to the Fc region of a human antibody.
Grafting only the hypervariable complementarity-determining regions (CDRs) from the murine antibody onto a human antibody framework. (correct answer)
Attaching polyethylene glycol (PEG) chains to the murine antibody to sterically hinder immune recognition.

Explanation: Humanization is a precise process aimed at making a non-human antibody less immunogenic while retaining its antigen specificity. The specificity is determined by the complementarity-determining regions (CDRs), which are small loops within the variable domain. The process involves identifying these murine CDRs and genetically grafting them onto the variable region framework of a human antibody. This results in an antibody that is mostly human (>90%) but has the antigen-binding specificity of the original murine antibody.

Question 12

Direct mutagenic activity of the immunosuppressant drugs on keratinocyte DNA.
A drug-induced increase in skin sensitivity to ultraviolet (UV) radiation.
Impairment of the immune system's ability to recognize and eliminate nascent malignant cells. (correct answer)
Chronic stimulation of keratinocyte proliferation by the biologic agents.

Question 13

The efficacy of a therapeutic monoclonal antibody like trastuzumab (anti-HER2) often depends on its Fc region, not just its antigen-binding Fab region. Which crucial anti-tumor effector function is directly mediated by the interaction of the antibody's Fc region with host immune cells?

Directly inducing apoptosis of the tumor cell upon binding to the HER2 receptor.
Neutralizing growth factors in the tumor microenvironment before they can bind to the HER2 receptor.
Internalizing into the tumor cell to deliver a conjugated cytotoxic drug payload.
Recruiting and activating natural killer (NK) cells to lyse the antibody-coated tumor cell. (correct answer)

Explanation: When you encounter questions about therapeutic monoclonal antibodies, focus on the dual nature of their mechanism: the Fab region provides specificity through antigen binding, while the Fc region mediates immune effector functions through interactions with host immune cells. Trastuzumab's anti-tumor efficacy relies heavily on antibody-dependent cellular cytotoxicity (ADCC). The Fc region of trastuzumab bound to HER2 on tumor cells serves as a recognition signal for NK cells, which express Fc gamma receptors (FcγRIIIa). This interaction activates NK cells to release cytotoxic granules containing perforin and granzymes, directly lysing the antibody-coated tumor cell. This is why answer D is correct – it describes the classical ADCC mechanism that's central to trastuzumab's therapeutic action. Option A is incorrect because trastuzumab doesn't directly induce apoptosis simply by binding HER2; any apoptotic effects occur through downstream signaling disruption, not direct Fc-mediated mechanisms. Option B misrepresents the mechanism – trastuzumab doesn't neutralize growth factors but rather blocks HER2 receptor signaling, and this blocking function involves the Fab region, not the Fc region. Option C describes antibody-drug conjugates (like ado-trastuzumab emtansine), where internalization delivers cytotoxic payloads, but this isn't the primary Fc-mediated effector function being tested. For pharmacology exams, remember that therapeutic antibodies work through multiple mechanisms simultaneously. When questions specifically ask about Fc region functions, think immune cell recruitment and activation – particularly ADCC mediated by NK cells and complement-dependent cytotoxicity.

Question 14

A patient with metastatic renal cell carcinoma is receiving high-dose interleukin-2 (IL-2) therapy. During treatment, the patient develops profound hypotension, tachycardia, and a 10 kg weight gain due to diffuse edema, requiring transfer to the ICU.

This clinical syndrome is a well-known toxicity of high-dose IL-2 and is primarily caused by what pathophysiological mechanism?

A type I hypersensitivity reaction leading to systemic mast cell degranulation and histamine release.
Drug-induced congestive heart failure resulting from direct myocardial toxicity.
Acute renal failure due to immune complex deposition in the glomeruli.
Systemic endothelial cell activation leading to increased vascular permeability and fluid extravasation. (correct answer)

Explanation: When you encounter questions about IL-2 therapy complications, focus on understanding how this immunotherapy agent affects the vascular system rather than looking for typical drug allergies or organ-specific toxicities. High-dose IL-2 causes a characteristic syndrome called capillary leak syndrome through systemic endothelial cell activation. IL-2 stimulates various immune cells that release inflammatory mediators, which then activate endothelial cells lining blood vessels throughout the body. This activation disrupts normal endothelial barrier function, dramatically increasing vascular permeability. Fluid, electrolytes, and proteins leak from the intravascular space into tissues, causing the classic triad: hypotension (from intravascular volume depletion), compensatory tachycardia, and massive fluid retention with weight gain. This makes D correct. Option A describes anaphylaxis, which would present with bronchospasm, urticaria, and rapid onset rather than the progressive fluid retention seen here. Option B suggests direct cardiac toxicity, but IL-2 doesn't primarily damage myocardium—the hypotension results from volume shifts, not heart failure. Option C points to immune complex glomerulonephritis, but while IL-2 can affect kidneys, the primary mechanism causing this patient's symptoms is vascular leak, not renal immune complex disease. Remember that IL-2's major dose-limiting toxicity is always capillary leak syndrome. When you see IL-2 questions describing hypotension with significant weight gain and edema, think "leaky blood vessels" rather than allergic reactions or direct organ toxicity. This pattern recognition will serve you well on immunotherapy questions.

Question 15

A biosimilar for adalimumab was initially approved based on robust comparative clinical trials in patients with rheumatoid arthritis. The regulatory agency subsequently approved the biosimilar for treating Crohn's disease, another approved indication for the reference product, without requiring new clinical trials in that specific population. This regulatory approval process is known as:

Off-label usage
Extrapolation (correct answer)
Interchangeability
Pharmacovigilance

Explanation: Extrapolation is a key concept in biosimilar development. It refers to the approval of a biosimilar for one or more indications held by the reference product for which the biosimilar itself was not studied in clinical trials. This is permitted if the totality of evidence supports biosimilarity and if the mechanism of action of the drug and the pathophysiology of the diseases are sufficiently similar across indications. This practice avoids redundant clinical trials and facilitates patient access.

Question 16

Anti-thymocyte globulin (ATG), derived from rabbits or horses, is used for induction immunosuppression in transplant patients. Which statement best describes a fundamental distinction between ATG and a monoclonal antibody like daclizumab?

ATG is a polyclonal preparation containing a spectrum of antibodies that recognize numerous different epitopes on T-cells. (correct answer)
ATG is a fully human protein, resulting in a lower incidence of serum sickness compared to the chimeric daclizumab.
ATG has a highly specific mechanism, targeting only the CD25 subunit of the IL-2 receptor on activated T-cells.
ATG functions by blocking T-cell signaling without causing cell depletion, a more gentle approach than monoclonal antibodies.

Explanation: The key difference is monoclonality versus polyclonality. A monoclonal antibody (like daclizumab, which targets CD25) is a homogenous preparation of a single antibody that recognizes only one specific epitope. In contrast, ATG is a polyclonal preparation, meaning it is a mixture of many different antibodies purified from the serum of an animal immunized with human thymocytes. These antibodies recognize a wide variety of antigens on the T-cell surface, leading to broad T-cell depletion through multiple mechanisms.

Question 17

A patient with Crohn's disease, who was previously well-controlled on infliximab, presents with a secondary loss of response. Therapeutic drug monitoring reveals subtherapeutic trough concentrations of infliximab and high titers of anti-drug antibodies (ADAs). The gastroenterologist plans to switch the patient to adalimumab.

What is the primary pharmacological rationale for expecting a better clinical outcome with adalimumab in this specific patient?

Adalimumab is a fully human monoclonal antibody and is less likely to elicit an immunogenic response compared to the chimeric infliximab. (correct answer)
Adalimumab targets a different inflammatory cytokine, interleukin-12, thereby bypassing the TNF-alpha pathway resistance.
Adalimumab is a smaller antibody fragment that possesses a higher affinity for TNF-alpha and can overcome the neutralizing effect of the existing ADAs.
As a pegylated biologic, adalimumab has a longer half-life and is shielded from recognition by the patient's immune system.

Explanation: The patient developed anti-drug antibodies (ADAs) to infliximab, which is a chimeric monoclonal antibody (containing mouse-derived variable regions). This immunogenicity is a common cause of treatment failure. The '-xi-' infix in infliximab denotes its chimeric nature. Adalimumab, denoted by the '-u-' infix, is a fully human monoclonal antibody. Switching to a less immunogenic, fully human antibody against the same target (TNF-alpha) is a standard strategy to overcome ADA-mediated resistance.

Question 18

A patient with severe ulcerative colitis shows a suboptimal response to vedolizumab, an integrin receptor antagonist. Therapeutic drug monitoring (TDM) reveals low trough concentrations of the drug, but testing for anti-drug antibodies (ADAs) is negative.

In the absence of ADAs, which patient-specific factor is the most likely contributor to the observed low drug concentrations?

Rapid clearance due to a high burden of intestinal inflammation and target antigen expression. (correct answer)
Accelerated hepatic metabolism due to a genetic polymorphism in a cytochrome P450 enzyme.
Poor adherence to the intravenous infusion schedule administered by the healthcare facility.
Increased renal clearance of the antibody due to co-morbid chronic kidney disease.

Explanation: The pharmacokinetics of many monoclonal antibodies are influenced by the 'target-mediated drug disposition' phenomenon. In highly inflammatory states, there is a higher expression of the drug's target (in this case, α4β7 integrin on lymphocytes) and increased protein catabolism. This leads to more drug binding to its target and being cleared from circulation, resulting in lower trough concentrations. This is a well-established reason for low drug levels in patients with severe disease, independent of immunogenicity.

Question 19

A pharmaceutical company is in the early stages of developing a new biologic agent intended for systemic administration. Compared to a traditional small-molecule drug, which pharmacokinetic property is most characteristic of this new biologic agent?

Extensive hepatic metabolism primarily via cytochrome P450 enzymes, leading to numerous drug-drug interactions.
High oral bioavailability allowing for convenient, non-invasive patient self-administration at home.
Clearance primarily through catabolism into peptides and amino acids, with minimal renal or hepatic excretion of the intact molecule. (correct answer)
A small volume of distribution largely confined to the intracellular space due to efficient transport across cell membranes.

Explanation: Biologics, such as monoclonal antibodies and fusion proteins, are large protein-based molecules. They are not metabolized by CYP450 enzymes nor are they significantly cleared by the kidneys as intact molecules. Instead, they are broken down (catabolized) into smaller peptides and amino acids by the reticuloendothelial system and target cells, which are then recycled by the body. This is a fundamental difference from small-molecule drugs.

Question 20

Directly inducing apoptosis of the tumor cell upon binding to the HER2 receptor.
Neutralizing growth factors in the tumor microenvironment before they can bind to the HER2 receptor.
Internalizing into the tumor cell to deliver a conjugated cytotoxic drug payload.
Recruiting and activating natural killer (NK) cells to lyse the antibody-coated tumor cell. (correct answer)